{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:13:31Z","timestamp":1787436811364,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Carl and Ellen Hertz Foundation"},{"name":"The Children\u2019s Cancer Foundation of Sweden","award":["53\/91"],"award-info":[{"award-number":["53\/91"]}]},{"name":"The Children\u2019s Cancer Foundation of Sweden","award":["62\/94"],"award-info":[{"award-number":["62\/94"]}]},{"name":"The Children\u2019s Cancer Foundation of Sweden","award":["72\/96"],"award-info":[{"award-number":["72\/96"]}]},{"name":"The Children\u2019s Cancer Foundation of Sweden","award":["98\/59"],"award-info":[{"award-number":["98\/59"]}]},{"DOI":"10.13039\/100008363","name":"The Danish Cancer Society","doi-asserted-by":"crossref","award":["91\u2013048"],"award-info":[{"award-number":["91\u2013048"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008363","name":"The Danish Cancer Society","doi-asserted-by":"crossref","award":["92\u2013017"],"award-info":[{"award-number":["92\u2013017"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008363","name":"The Danish Cancer Society","doi-asserted-by":"crossref","award":["95\u2013100-28"],"award-info":[{"award-number":["95\u2013100-28"]}],"id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The JPC Foundation"},{"name":"The Lundbeck Foundation","award":["38\/99"],"award-info":[{"award-number":["38\/99"]}]},{"name":"The Minister Erna Hamilton Foundation"},{"name":"The Nordic Cancer Union","award":["56\u20139257"],"award-info":[{"award-number":["56\u20139257"]}]},{"name":"The Nordic Cancer Union","award":["56\u2013100-03\u20139102"],"award-info":[{"award-number":["56\u2013100-03\u20139102"]}]},{"name":"United States National Institutes of Health","award":["RO1-GM28157"],"award-info":[{"award-number":["RO1-GM28157"]}]},{"name":"United States National Institutes of Health","award":["RO1-GM35720"],"award-info":[{"award-number":["RO1-GM35720"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["462065145"],"award-info":[{"award-number":["462065145"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012320","name":"Otto-von-Guericke-Universit\u00e4t Magdeburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012320","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the treatment of childhood acute lymphoblastic leukemia (ALL), current protocols combine initial high-dose multiagent chemotherapy with prolonged oral therapy with 6-mercaptopurine (6MP) and low-dose methotrexate (MTX) maintenance therapy. Decades of research on ALL treatment have resulted in survival rates of approximately 90%. However, dose-response relationships vary widely between patients and insight into the influencing factors, that would allow for improved personalized treatment management, is insufficient. We use a detailed data set with measurements of thioguanine nucleotides and MTX in red blood cells and absolute neutrophil count (ANC) to develop pharmacokinetic models for 6MP and MTX, as well as a pharmacokinetic\u2013pharmacodynamic (PKPD) model capable of predicting individual ANC levels and thus contributing to the development of personalized treatment strategies. Here, we show that integrating metabolite measurements in red blood cells into the full PKPD model improves results when less data is available, but that model predictions are comparable to those of a fixed pharmacokinetic model when data availability is not limited, providing further evidence of the quality of existing models. With this comprehensive model development leading to dynamics similar to simpler models, we validate the suitability of this model structure and provide a foundation for further exploration of maintenance therapy strategies through simulation and optimization.<\/jats:p>","DOI":"10.1038\/s41598-023-38414-0","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T15:05:35Z","timestamp":1689865535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetic\u2013pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"13","author":[{"given":"Anna","family":"Gebhard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lilienthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Rauh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjeld","family":"Schmiegelow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linea Natalie","family":"Toksvang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Zierk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"issue":"11","key":"38414_CR1","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba, H. & Mullighan, C. G. Pediatric acute lymphoblastic leukemia. Haematologica 105(11), 2524\u20132539 (2020).","journal-title":"Haematologica"},{"key":"38414_CR2","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541\u20131552 (2015).","journal-title":"N. Engl. J. Med."},{"key":"38414_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/s41375-022-01591-4","volume":"36","author":"LN Toksvang","year":"2022","unstructured":"Toksvang, L. N., Lee, S. H., Yang, J. J. & Schmiegelow, K. Maintenance therapy for acute lymphoblastic leukemia: Basic science and clinical translations. Leukemia 36, 1749\u20131758 (2022).","journal-title":"Leukemia"},{"issue":"12","key":"38414_CR4","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/pbc.26139","volume":"63","author":"K Schmiegelow","year":"2016","unstructured":"Schmiegelow, K. et al. Maintenance therapy of childhood acute lymphoblastic leukemia revisited: Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?. Pediatr. Blood Cancer 63(12), 2104\u20132111 (2016).","journal-title":"Pediatr. Blood Cancer"},{"issue":"5","key":"38414_CR5","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cell.2015.11.002","volume":"163","author":"F Michor","year":"2015","unstructured":"Michor, F. & Beal, K. Improving cancer treatment via mathematical modeling: Surmounting the challenges is worth the effort. Cell 163(5), 1059\u20131063 (2015).","journal-title":"Cell"},{"key":"38414_CR6","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1007\/s11538-019-00640-x","volume":"81","author":"R Brady","year":"2019","unstructured":"Brady, R. & Enderling, H. Mathematical models of cancer: When to predict novel therapies, and when not to. Bull. Math. Biol. 81, 3722\u20133731 (2019).","journal-title":"Bull. Math. Biol."},{"key":"38414_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.imu.2021.100534","volume":"23","author":"J Malinzi","year":"2021","unstructured":"Malinzi, J., Basita, K. B., Padidar, S. & Adeola, H. A. Prospect for application of mathematical models in combination cancer treatments. Inform. Med. Unlocked 23, 100534 (2021).","journal-title":"Inform. Med. Unlocked"},{"key":"38414_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40324-022-00296-z","volume":"79","author":"S Chuli\u00e1n","year":"2022","unstructured":"Chuli\u00e1n, S., Martnez-Rubio, A., Rosa, M. & P\u00e9rez-Garc\u00e1, V. M. Mathematical models of leukaemia and its treatment: A review. SeMA J. 79, 441\u2013486 (2022).","journal-title":"SeMA J."},{"issue":"4","key":"38414_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/imammb\/dqy017","volume":"36","author":"TT Le","year":"2019","unstructured":"Le, T. T. et al. A mathematical model of white blood cell dynamics during maintenance therapy of childhood acute lymphoblastic leukemia. Math. Med. Biol. A J. IMA 36(4), 471\u2013488 (2019).","journal-title":"Math. Med. Biol. A J. IMA"},{"key":"38414_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fphys.2020.00217","volume":"11","author":"F Jost","year":"2020","unstructured":"Jost, F. et al. Model-based simulation of maintenance therapy of childhood acute lymphoblastic leukemia. Front. Physiol. 11, 217 (2020).","journal-title":"Front. Physiol."},{"issue":"10","key":"38414_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0109623","volume":"9","author":"D Jayachandran","year":"2014","unstructured":"Jayachandran, D., Rundell, A. E., Hannemann, R. E., Vik, T. A. & Ramkrishna, D. Optimal chemotherapy for leukemia: A model-based strategy for individualized treatment. PLOS ONE 9(10), 1\u201318 (2014).","journal-title":"PLOS ONE"},{"issue":"2","key":"38414_CR12","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/sj.leu.2402373","volume":"16","author":"T Dervieux","year":"2002","unstructured":"Dervieux, T., Hancock, M., Evans, W., Pui, C.-H. & Relling, M. Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine. Leukemia 16(2), 209\u2013212 (2002).","journal-title":"Leukemia"},{"issue":"5","key":"38414_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","volume":"146","author":"K Schmiegelow","year":"2009","unstructured":"Schmiegelow, K. Advances in individual prediction of methotrexate toxicity: A review. Br. J. Haematol. 146(5), 489\u2013503 (2009).","journal-title":"Br. J. Haematol."},{"issue":"1","key":"38414_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3109\/08880018609031198","volume":"3","author":"G L\u00f6nnerholm","year":"1986","unstructured":"L\u00f6nnerholm, G., Kreuger, A., Lindstr\u00f6m, B., Ludvigsson, J. & Myrdal, U. Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children. Pediatr. Hematol. Oncol. 3(1), 27\u201335 (1986).","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"24","key":"38414_CR15","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2002","unstructured":"Friberg, L. E., Henningsson, A., Maas, H., Nguyen, L. & Karlsson, M. O. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J. Clin. Oncol. 20(24), 4713\u20134721 (2002).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"38414_CR16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1200\/JCO.2003.04.039","volume":"21","author":"K Schmiegelow","year":"2003","unstructured":"Schmiegelow, K. et al. Intensification of mercaptopurine\/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J. Clin. Oncol. 21(7), 1332\u20131339 (2003).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"38414_CR17","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1038\/sj.leu.2401961","volume":"14","author":"G Gustafsson","year":"2000","unstructured":"Gustafsson, G. et al. Improving outcome through two decades in childhood all in the nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 14(12), 2267\u20132275 (2000).","journal-title":"Leukemia"},{"key":"38414_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-09146-9","volume":"7","author":"S Longeville","year":"2017","unstructured":"Longeville, S. & Stingaciu, L.-R. Hemoglobin diffusion and the dynamics of oxygen capture by red blood cells. Sci. Rep. 7, 1\u201310 (2017).","journal-title":"Sci. Rep."},{"issue":"7","key":"38414_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1097\/MPH.0000000000000206","volume":"36","author":"K Schmiegelow","year":"2014","unstructured":"Schmiegelow, K., Nielsen, S. N., Frandsen, T. L. & Nersting, J. Mercaptopurine\/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J. Pediatr. Hematol. \/Oncol. 36(7), 503\u2013517 (2014).","journal-title":"J. Pediatr. Hematol. \/Oncol."},{"issue":"7","key":"38414_CR20","first-page":"2423","volume":"8","author":"JC Panetta","year":"2002","unstructured":"Panetta, J. C., Wall, A., Pui, C.-H., Relling, M. V. & Evans, W. E. Methotrexate intracellular disposition in acute lymphoblastic leukemia: A mathematical model of \u03b3-glutamyl hydrolase activity. Clin. Cancer Res. 8(7), 2423\u20132429 (2002).","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"38414_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1001019","volume":"6","author":"JC Panetta","year":"2010","unstructured":"Panetta, J. C., Sparreboom, A., Pui, C.-H., Relling, M. V. & Evans, W. E. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLOS Comput. Biol. 6(12), 1\u201313 (2010).","journal-title":"PLOS Comput. Biol."},{"issue":"6","key":"38414_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40262-013-0052-y","volume":"52","author":"J Korell","year":"2013","unstructured":"Korell, J. et al. A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clin. Pharmacokinet. 52(6), 475\u2013485 (2013).","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"38414_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10928-014-9354-4","volume":"41","author":"K Ogungbenro","year":"2014","unstructured":"Ogungbenro, K., Aarons, L., CRESim Epi-CRESim Project Groups. Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate. J. Pharmacokinet. Pharmacodyn. 41(2), 159\u2013171 (2014).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"1","key":"38414_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00280-019-03977-1","volume":"85","author":"SE Medellin-Garibay","year":"2020","unstructured":"Medellin-Garibay, S. E. et al. Population pharmacokinetics of methotrexate in mexican pediatric patients with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 85(1), 21\u201331 (2020).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"38414_CR25","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1002\/1097-0142(19811201)48:11<2427::AID-CNCR2820481115>3.0.CO;2-M","volume":"48","author":"MD Costa","year":"1981","unstructured":"Costa, M. D. & Iqbal, M. P. The transport and accumulation of methotrexate in human erythrocytes. Cancer 48, 2427\u20132432 (1981).","journal-title":"Cancer"},{"issue":"2","key":"38414_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1089\/cdd.1987.4.119","volume":"4","author":"N Lena","year":"1987","unstructured":"Lena, N., Imbert, A., Brunet, P., Cano, J. & Carcassonne, Y. Kinetics of methotrexate and its metabolites in red blood cells. Cancer Drug Deliv. 4(2), 119\u2013127 (1987).","journal-title":"Cancer Drug Deliv."},{"key":"38414_CR27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/BF00296766","volume":"9","author":"A Schalhorn","year":"1982","unstructured":"Schalhorn, A., Sauer, H., Wilmanns, W. & Stupp-Poutot, G. Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate. Cancer Chemother. Pharmacol. 9, 65\u201369 (1982).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"38414_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/BF00257363","volume":"21","author":"H Schr\u00f8der","year":"1988","unstructured":"Schr\u00f8der, H., Fogh, K. & Herlin, T. In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes. Cancer Chemother. Pharmacol. 21, 150\u2013155 (1988).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"38414_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/j.1365-2125.2008.03248.x","volume":"66","author":"AF Hawwa","year":"2008","unstructured":"Hawwa, A. F. et al. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br. J. Clin. Pharmacol. 66, 517\u2013528 (2008).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"38414_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/clpt.1986.178","volume":"40","author":"L Lennard","year":"1986","unstructured":"Lennard, L., Keen, D. & Lilleyman, J. Oral 6-mercaptopurine in childhood leukemia: Parent drug pharmacokinetics and active metabolite concentrations. Clin. Pharmacol. Therapeutics 40(3), 287\u2013292 (1986).","journal-title":"Clin. Pharmacol. Therapeutics"},{"issue":"3","key":"38414_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom, L., Pihlgren, P. & Jonsson, N. Psn-toolkit: A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Progr. Biomed. 79(3), 241\u2013257 (2005).","journal-title":"Comput. Methods Progr. Biomed."},{"key":"38414_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12532-018-0139-4","volume":"11","author":"JA Andersson","year":"2019","unstructured":"Andersson, J. A., Gillis, J., Horn, G., Rawlings, J. B. & Diehl, M. CasADi: A software framework for nonlinear optimization and optimal control. Math. Progr. Comput. 11, 1\u201336 (2019).","journal-title":"Math. Progr. Comput."},{"issue":"3","key":"38414_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1145\/1089014.1089020","volume":"31","author":"AC Hindmarsh","year":"2005","unstructured":"Hindmarsh, A. C. et al. SUNDIALS: Suite of nonlinear and differential\/algebraic equation solvers. ACM Trans. Math. Softw. (TOMS) 31(3), 363\u2013396 (2005).","journal-title":"ACM Trans. Math. Softw. (TOMS)"},{"issue":"1","key":"38414_CR34","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1002\/1097-0215(20010101)91:1<120::AID-IJC1021>3.0.CO;2-Y","volume":"91","author":"DS Cowan","year":"2001","unstructured":"Cowan, D. S. & Tannock, I. F. Factors that influence the penetration of methotrexate through solid tissue. Int. J. Cancer 91(1), 120\u2013125 (2001).","journal-title":"Int. J. Cancer"},{"issue":"2","key":"38414_CR35","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0163-7258(81)90045-0","volume":"15","author":"JC White","year":"1981","unstructured":"White, J. C. & Mikulecky, D. C. Application of network thermodynamics to the computer modeling of the pharmacology of anticancer agents: A network model for methotrexate action as a comprehensive example. Pharmacol. Therapeutics 15(2), 251\u2013291 (1981).","journal-title":"Pharmacol. Therapeutics"},{"issue":"11","key":"38414_CR36","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1177\/000992287901801104","volume":"18","author":"T Small","year":"1979","unstructured":"Small, T. & Oski, F. A. The mean corpuscular volume (MCV) in children with acute lymphoblastic leukemia. Clin. Pediatr. 18(11), 687\u2013691 (1979).","journal-title":"Clin. Pediatr."},{"issue":"1","key":"38414_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10928-017-9560-y","volume":"45","author":"D De C\u00e2mara Souza","year":"2018","unstructured":"De C\u00e2mara Souza, D. et al. Transit and lifespan in neutrophil production: Implications for drug intervention. J. Pharmacokinet. Pharmacodyn. 45(1), 59\u201377 (2018).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"42","key":"38414_CR38","doi-asserted-by":"publisher","first-page":"9450","DOI":"10.1126\/sciadv.abn9450","volume":"8","author":"A Puy","year":"2022","unstructured":"Puy, A. et al. Models with higher effective dimensions tend to produce more uncertain estimates. Sci. Adv. 8(42), 9450 (2022).","journal-title":"Sci. Adv."},{"issue":"7","key":"38414_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204540","volume":"14","author":"F Jost","year":"2019","unstructured":"Jost, F., Schalk, E., Rinke, K., Fischer, T. & Sager, S. Mathematical models for cytarabine-derived myelosuppression in acute myeloid leukaemia. PLOS ONE 14(7), e0204540 (2019).","journal-title":"PLOS ONE"},{"issue":"12","key":"38414_CR40","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1109\/TBME.2020.2982749","volume":"67","author":"F Jost","year":"2020","unstructured":"Jost, F. et al. Model-based optimal AML consolidation treatment. IEEE Trans. Biomed. Eng. 67(12), 3296\u20133306 (2020).","journal-title":"IEEE Trans. Biomed. Eng."},{"issue":"3","key":"38414_CR41","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/bcp.12209","volume":"77","author":"J Korell","year":"2014","unstructured":"Korell, J. et al. Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. Br. J. Clin. Pharmacol. 77(3), 493\u2013497 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"4","key":"38414_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S1470-2045(17)30154-7","volume":"18","author":"SN Nielsen","year":"2017","unstructured":"Nielsen, S. N. et al. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): A prospective substudy of a phase 3 trial. Lancet Oncol. 18(4), 515\u2013524 (2017).","journal-title":"Lancet Oncol."},{"key":"38414_CR43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41375-021-01182-9","volume":"36","author":"LN Toksvang","year":"2022","unstructured":"Toksvang, L. N. et al. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: An IPD meta-analysis. Leukemia 36, 33\u201341 (2022).","journal-title":"Leukemia"},{"issue":"5","key":"38414_CR44","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00280-016-3151-2","volume":"78","author":"SN Nielsen","year":"2016","unstructured":"Nielsen, S. N. et al. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 78(5), 983\u2013994 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"17","key":"38414_CR45","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"R Mosteller","year":"1987","unstructured":"Mosteller, R. Simplified calculation of body surface area. N. Engl. J. Med. 317(17), 1098 (1987).","journal-title":"N. Engl. J. Med."},{"key":"38414_CR46","unstructured":"Brunton, L.\u00a0L., Lazo, J.\u00a0S. & Parker, K. Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics. 11 edn (McGraw-Hill, New York, 2005)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38414-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38414-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38414-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T15:20:01Z","timestamp":1689866401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38414-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38414"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38414-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"21 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.S. declares the following competing interests: Speaker and\/or Advisory Board Honoraria from Illumina (2021), Jazz Pharmaceuticals (2020, 2021, 2023) and Servier (2020, 2021); Speaker fee from Amgen (2020, 2021) and Medscape (2020, 2021); Educational grants from Servier (2020, 2021, 2023); Research grant from Novo Nordisk Foundation (2020, 2022). All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11749"}}